Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395742 | 1.00 | PTGES (0.48) | PTGESCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL397343 | 0.92 | ALDH1A1 (0.51) | PTGESCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL435164 | 0.85 | ALDH1A1 (0.50) | PTGESALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL3596142 | 0.83 | ALDH1A1 (0.54) | PTGESALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL1169912 | 0.78 | ALDH1A1 (0.51) | PTGESALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL1170426 | 0.75 | KMT2A (0.45) | ALDH1A1KDM4EHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL1170425 | 0.75 | KMT2A (0.45) | ALDH1A1KDM4EHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL393916 | 0.73 | KMT2A (0.49) | ALDH1A1KDM4EHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL393917 | 0.73 | KMT2A (0.49) | ALDH1A1KDM4EHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL12867415 | 0.73 | KMT2A (0.49) | ALDH1A1KDM4EHSD17B10LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101620-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1605752-B1 | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. | CYTOKINETICS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110112154-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-7888373-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112154-A1 | Compounds, compositions and methods | TNNI3, TNNT2, MYLK2 | PTGES 3530/4885CYP3A4 4605/4885CYP2C9 4053/4885 |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | PTGES 3753/4885CYP3A4 4735/4885CYP2C9 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.